These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 35365341)
1. Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks. Estivariz CF; Kovacs SD; Mach O Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A113-A121. PubMed ID: 35365341 [TBL] [Abstract][Full Text] [Related]
2. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa. Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733 [TBL] [Abstract][Full Text] [Related]
3. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180 [TBL] [Abstract][Full Text] [Related]
4. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever. Orenstein WA; Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328 [TBL] [Abstract][Full Text] [Related]
6. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. Duintjer Tebbens RJ; Thompson KM J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871 [TBL] [Abstract][Full Text] [Related]
7. Ensuring preparedness for potential poliomyelitis outbreaks: Recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP). Alexander L; Birkhead G; Guerra F; Helms C; Hinman A; Katz S; LeBaron CW; Modlin J; Murphy TV; ; Arch Pediatr Adolesc Med; 2004 Dec; 158(12):1106-12. PubMed ID: 15583093 [TBL] [Abstract][Full Text] [Related]
8. Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization. Thompson KM; Kalkowska DA; Kidd SE; Burns CC; Badizadegan K Vaccine; 2024 Feb; 42(4):819-827. PubMed ID: 38218668 [TBL] [Abstract][Full Text] [Related]
9. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016. Immunization Systems Management Group of the Global Polio Eradication Initiative MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(25):699-702. PubMed ID: 26135591 [TBL] [Abstract][Full Text] [Related]
10. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. Duintjer Tebbens RJ; Hampton LM; Thompson KM BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198 [TBL] [Abstract][Full Text] [Related]
13. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016. Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D; MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675 [TBL] [Abstract][Full Text] [Related]
14. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep; 1997 Jan; 46(RR-3):1-25. PubMed ID: 9026708 [TBL] [Abstract][Full Text] [Related]
16. Polio endgame: the global switch from tOPV to bOPV. Garon J; Seib K; Orenstein WA; Ramirez Gonzalez A; Chang Blanc D; Zaffran M; Patel M Expert Rev Vaccines; 2016 Jun; 15(6):693-708. PubMed ID: 26751187 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan. Saleem AF; Yousafzai MT; Mach O; Khan A; Quadri F; Weldon WC; Oberste MS; Zaidi SS; Alam MM; Sutter RW; Zaidi AKM Vaccine; 2018 Mar; 36(13):1766-1771. PubMed ID: 29477307 [TBL] [Abstract][Full Text] [Related]
18. Anomalous observations on IPV and OPV vaccination. John TJ Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328 [TBL] [Abstract][Full Text] [Related]
19. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. Thompson KM; Duintjer Tebbens RJ BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878 [TBL] [Abstract][Full Text] [Related]
20. Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014. Liu Y; Wang J; Liu S; Du J; Wang L; Gu W; Xu Y; Zuo S; Xu E; An Z Vaccine; 2017 Mar; 35(9):1281-1286. PubMed ID: 28161421 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]